Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab

Retrospective Study Assessing Molecular Features Predicting Response or Resistance to Cetuximab Therapy in Metastatic Colorectal Cancer Patients

The primary objective is to identify molecular features predicting response or resistance to cetuximab

Secondary objective is to investigate association of genomic status of EGFR and HER-2 genes with clinical outcome, including objective response, time to progression and survival

Inclusion Criteria:

• Histologically confirmed diagnosis of colorectal cancer with available tumor tissue and clinical data; presence of at least one measurable lesion.

Exclusion Criteria:

• Less than 3 weeks after completion of previous radiotherapy